Monday, July 20, 2020, 5:00 PM – 6:00 PM ET

Recent Advances in Medical Oncology: Triple-Negative Breast Cancer

Join us on Monday, July 20 for the live webinar
5:00 PM – 6:00 PM ET
1 AMA PRA Category 1 CreditTM


Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, Texas

Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California


Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of ASCO20 Virtual. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

This activity is supported by education grants from Abbvie Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Merck, Puma Biotechnology Inc and Seattle Genetics.

Module 1: Current and Future Role of Immune Checkpoint Inhibition in the Treatment of Breast Cancer

  • Current indications for PD-L1, microsatellite instability (MSI) and tumor mutational burden testing in patients with metastatic triple-negative breast cancer (mTNBC); implications of positive test results for patient outcomes and current management
  • Key efficacy and safety findings from the Phase III IMpassion130 trial supporting the FDA approval of atezolizumab with nab paclitaxel as first-line therapy for mTNBC and integration of this approach into clinical practice
  • Design, eligibility criteria and available efficacy and safety findings from the Phase III KEYNOTE-355 trial evaluating chemotherapy with or without pembrolizumab for previously untreated mTNBC; potential role of pembrolizumab in combination with chemotherapy
  • Available and emerging results from Phase III trials evaluating pembrolizumab or atezolizumab in combination with chemotherapy as neoadjuvant therapy for TNBC
  • Potential application of neoadjuvant checkpoint inhibition as treatment for TNBC

Module 2: Integration of PARP Inhibition into the Care of Patients with Metastatic Breast Cancer with a BRCA Mutation; Other Recent Therapeutic Advances in TNBC

  • Frequency of germline BRCA mutations and other genomic alterations that confer sensitivity to PARP inhibitors in patients with breast cancer; guideline-endorsed indications for genetic testing in patients with TNBC
  • Data supporting the FDA approvals of olaparib and talazoparib for patients with metastatic HER2-negative breast cancer with germline BRCA mutations; factors affecting sequencing with other therapies
  • Emerging research data evaluating the efficacy of olaparib in patients with metastatic breast cancer and somatic BRCA1/2 mutations or mutations in other genes involved in the DNA damage response
  • Biologic rationale for the evaluation of PARP inhibitors, alone or in combination with other agents (eg, chemotherapy, immune checkpoint inhibitors), in the treatment of breast cancer
  • Key efficacy and safety results from clinical trials evaluating veliparib in combination with platinum-based chemotherapy for patients with metastatic breast cancer and germline BRCA mutations; clinical implications
  • Available data with and ongoing investigation of PARP inhibition in the adjuvant and neoadjuvant settings
  • Efficacy and safety data with the recently FDA-approved antibody-drug conjugate sacituzumab govitecan in patients with recurrent mTNBC; other recent therapeutic advances in TNBC

Target Audience
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.

Learning Objectives

  • Appreciate the biologic rationale for, available data with and potential long-term benefits of anti-PD-1/PD-L1 antibody therapy for patients with metastatic triple-negative breast cancer (mTNBC).
  • Evaluate published efficacy and safety data with the use of PARP inhibitors for mTNBC harboring a germline BRCA1/2 mutation or other DNA repair pathway abnormality, and consider the diagnostic and therapeutic implications of these findings for nonresearch clinical care.
  • Appraise available data supporting the efficacy of anti-PD-L1/PD-L1 antibody therapy combined with chemotherapy for newly diagnosed PD-L1-positive mTNBC, and use this information to identify patients who may be appropriate for this approach in clinical practice.
  • Assess the biologic rationale for ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies for mTNBC in order to effectively communicate to patients the potential benefits of trial participation.
  • Understand the mechanisms of action, early data and ongoing research with other novel agents and treatment strategies under development for TNBC.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr O’ShaughnessyAdvisory Committee and Consulting Agreements: AbbVie Inc, Agendia Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Genomic Health Inc, GRAIL, Halozyme Inc, Heron Therapeutics, Immunomedics Inc, Ipsen Biopharmaceuticals Inc, Jounce Therapeutics, Lilly, Merck, Myriad Genetic Laboratories Inc, Novartis, Odonate Therapeutics, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Seattle Genetics, Syndax Pharmaceuticals Inc. Dr RugoConsulting Agreements: Puma Biotechnology Inc, Samsung Bioepis; Contracted Research: Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Lilly, MacroGenics Inc, Merck, Novartis, OBI Pharma Inc, Odonate Therapeutics, Pfizer Inc, Seattle Genetics; Paid Travel: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, MacroGenics Inc, Merck, Mylan NV, Novartis, Pfizer Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

— Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Merck, Puma Biotechnology Inc and Seattle Genetics.